These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. Abali H; Celik I Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482 [TBL] [Abstract][Full Text] [Related]
44. Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting. Kirchner V; Aapro M; Alberto P; O'Grady P; Busch B; Boyce M Ann Oncol; 1993 Jun; 4(6):481-4. PubMed ID: 8353090 [TBL] [Abstract][Full Text] [Related]
45. [Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study]. Nukariya N; Kobayashi K; Ishihara Y; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H Gan To Kagaku Ryoho; 1996 May; 23(6):757-71. PubMed ID: 8645027 [TBL] [Abstract][Full Text] [Related]
46. The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting. Watters J; Riley M; Pedley I; Whitehead A; Overend M; Goss I; Allgar V Clin Oncol (R Coll Radiol); 2001; 13(6):422-6. PubMed ID: 11824878 [TBL] [Abstract][Full Text] [Related]
47. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Sorbe B Ann Oncol; 1993; 4 Suppl 3():39-42. PubMed ID: 8363999 [TBL] [Abstract][Full Text] [Related]
48. [The prevention and treatment of nausea and vomiting during cancer chemotherapy]. Shparyk IaV; Bilyns'kyĭ BT; Koval'chuk IV; Petriv RM; Kachmar TB; Ohorchak MA Lik Sprava; 1997; (4):148-52. PubMed ID: 9471361 [TBL] [Abstract][Full Text] [Related]
49. A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Merrouche Y; Catimel G; Rebattu P; Dumortier A; Guastalla JP; O'Grady P; Clavel M Ann Oncol; 1994 Jul; 5(6):549-51. PubMed ID: 7918128 [TBL] [Abstract][Full Text] [Related]
50. [Experience with the clinical use of navoban]. Voznyĭ EK; Dobrovol'skaia NI; Volkova LA Vopr Onkol; 1995; 41(1):70-1. PubMed ID: 7667947 [No Abstract] [Full Text] [Related]
51. Prevention of chemotherapy-induced nausea and emesis in patients responding poorly to previous antiemetic therapy. Comparing tropisetron with optimised standard antiemetic therapy. Bruntsch U; Drechsler S; Hiller E; Eiermann W; Tulusan AH; Bühner M; Hartenstein R; Koenig HJ; Gallmeier WM Drugs; 1992; 43 Suppl 3():23-6. PubMed ID: 1380429 [TBL] [Abstract][Full Text] [Related]
52. Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Van Belle SJ; Stamatakis L; Bleiberg H; Cocquyt VF; Michel J; de Bruijn KM Ann Oncol; 1994 Nov; 5(9):821-5. PubMed ID: 7848884 [TBL] [Abstract][Full Text] [Related]
53. [Antiemetic treatment and chemotherapy: general review]. Lecomte S; Adenis A; Bonneterre J Rev Med Interne; 1994; 15(11):752-69. PubMed ID: 7846392 [TBL] [Abstract][Full Text] [Related]
54. Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. Dogliotti L; Antonacci RA; Pazè E; Ortega C; Berruti A; Faggiuolo R Drugs; 1992; 43 Suppl 3():6-10. PubMed ID: 1380432 [TBL] [Abstract][Full Text] [Related]
56. [Use of Navoban in pediatric oncology]. Safonova SA; Kolygin BA; Punanov IA; Borodina AF Vopr Onkol; 1996; 42(6):72-3. PubMed ID: 9123909 [TBL] [Abstract][Full Text] [Related]
57. [The use of navoban in the therapy of oncology patients with highly emetic treatments]. Russel AJ Vopr Onkol; 1995; 41(1):87-90. PubMed ID: 7667952 [No Abstract] [Full Text] [Related]
58. Optimal selection of antiemetics in children receiving cancer chemotherapy. Roila F; Aapro M; Stewart A Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872 [TBL] [Abstract][Full Text] [Related]
59. Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments. Cefalo G; Rottoli L; Armiraglio A; Pagan MG Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):242-5. PubMed ID: 8037343 [TBL] [Abstract][Full Text] [Related]
60. Tropisetron (Navoban) compared with alizapride in the control of emesis induced by cyclophosphamide-containing regimens. De Nigris A; Paladini G; Giosa F; Sfeir C; Pagan MG; Maltoni C Eur J Cancer; 1994; 30A(12):1902-3. PubMed ID: 7880624 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]